We create high-quality medicines and make them accessible to people who need them. Global experts with a local presence, we think creatively and act practically. We develop innovative solutions that transform people’s lives, for a healthier world wherever we are.

Messages from the Board

quotemark graphic

Our diversified business model enabled a resilient core performance in 2022 as we continued to deliver on our purpose."

Said Darwazah Said Darwazah, Executive Chairman and CEO

Four reasons to invest in Hikma

We have a strong business model with significant opportunities to further enhance our portfolio to drive growth and deliver value for shareholders.


Our business model

Our business model enables us to respond to the many opportunities and challenges we face.

Our strategy

By focusing on our strategy, we will deliver sustainable growth over the long-term.

Our operations

Our Injectables business supplies hospitals across our markets with generic injectables, supported by our manufacturing facilities in the US, Europe and MENA. 

Core revenue ($m)

45% of Group revenue (2021: 41%)

Our Branded business supplies branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.

Revenue ($m)

27% of Group revenue (2021: 26%)

Our Generics business supplies oral and other
non‑injectable generic and specialty branded products in the US retail market, leveraging our
state-of-art manufacturing facility in Columbus, Ohio.

Revenue ($m)

27% of Group revenue (2021: 32%)